Swiss physicians to be reimbursed per NIOX MINO® test

Swiss physicians to be reimbursed per NIOX MINO® test 

SOLNA, Sweden—9 March 2009—Aerocrine AB (OMX Nordic Exchange: AERO) announced
today that reimbursement for the routine measurement of airway inflammation has
been introduced in the Swiss healthcare system.

From March 2009 onwards, specialists that measure airway inflammation using
Aerocrine's NIOX MINO instrument will receive €36 per adult and €45 per child
for each test. This reimbursement means that physicians specialising in airway
diseases can use the test routinely in daily clinical work.

Asthma is one of the world's most widespread diseases, affecting more children
than adults. Symptoms and asthma attacks are caused by inflammation in the
airways. Measuring this inflammation was not possible in the past, so diagnosis
and treatment was largely based on patient symptoms. Anti-inflammatory drugs,
such as inhaled cortisone, are a cornerstone of asthma therapy. Measuring airway
inflammation offers answers to which patients will respond to treatment, and
provides an objective measure of therapeutic effect. By measuring inflammation
regularly, doctors also get answers to whether patients are following their
prescribed anti-inflammatory treatment, and that their asthma is under control.
Regular measurement using NIOX MINO tests enable improved treatment and care of
asthma patients, which in turn, is cost-effective.

“This is a big success and milestone for Trimedal, our highly capable
distributor in Switzerland,” commented Paul de Potocki, Aerocrine's CEO,
“reimbursement from national health insurance systems is a vital prerequisite
for the broad-based and routine usage of Aerocrine's products.”

For more information, please contact:

Paul de Potocki, President & CEO, phone: +46 8 629 0782, 0706- 69 96 18
Lena Kajland-Wilén, Marketing Director, phone:  +46 8 629 0784, 0706-29 07 84

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in the technology to monitor and manage airway inflammation, Aerocrine
markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
9.30 am on 9 March 2009.